Validation Data Gallery
Technical Specifications
| GeneID | 3082 |
| Species | Human |
| Expression | HEK293 |
| Activity | 5-25 ng/mL |
| Specific Activity | minimally 2.50 x 105 IU/mg |
| Purity | >95% |
| Endotoxin | <1 EU/µg |
| Accession Number | P14210 |
| Molecular Mass | 85 kDa reduced, 70 kDa non-reduced, single chain, glycosylated |
| Formulation | 1x PBS, See Certificate of Analysis for details |
| Species Reactivity | human,monkey,mouse |
Stability and Reconstitution
| Stability and Storage | Product Form | Temperature Conditions | Storage Time (From Date of Receipt) |
|---|---|---|---|
| Lyophilized | -20°C to -80°C | Until Expiry Date | |
| Lyophilized | Room Temperature | 2 weeks | |
| Reconstituted as per CofA | -20°C to -80°C | 6 months | |
| Reconstituted as per CofA | 4°C | 1 week | |
| Avoid repeated freeze-thaw cycles. | |||
| Reconstitution | Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix. |
Background
Hepatocyte growth factor (HGF) is the most potent mitogen of mature hepatocytes in primary culture. It is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin (PMID 1530787, 2531289). HGF exerts a variety of effects on several cells, such as inflammation, tissue repair, morphogenesis, angiogenesis, tumour propagation, immunomodulation of viral infections and cardio-metabolic activities (PMID: 1846706; 15070743; 1383237; 1827664).
Synonyms
F TCF, Hepatocyte growth factor, Hepatopoeitin A, HGF, HGFB, HPTA, Scatter factor, SF
Publications
| Species | Title |
|---|---|
Nat Commun Selectively targeting the AdipoR2-CaM-CaMKII-NOS3 axis by SCM-198 as a rapid-acting therapy for advanced acute liver failure | |
Cell Death Dis Dissecting endometrial cancer complexity in response to standard and targeted therapies. | |
Pharmacol Res The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition | |
Cell Death Discov Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. | |
Cell Death Discov PARP1 mediated PARylation contributes to myogenic progression and glucocorticoid transcriptional response | |
Stem Cell Res Ther Novel stem cell therapy for cerebral palsy using stem cells from human exfoliated deciduous teeth. |
